Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisone for COVID-19 viral pneumonia
2020-001553-48Phase 2Terminated
- Sponsor
- Hospices Civils de Lyon
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of prednisone in coronavirus pneumonia and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Theoretical indication for intensive care transfer due to respiratory status at day 7 after randomization. Started Apr 2020; status: terminated.
02
Drugs
prednisone
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001553-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001553-48.